Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18763535 | 0.84 | LMNA (0.42) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19831132 | 0.83 | GPR55 (0.35) | NPC1RAB9AESR1ESR2SMN1; SMN2 | |
| SCHEMBL24867544 | 0.83 | CYP3A4 (0.38) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19998188 | 0.79 | ALDH1A1 (0.37) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24867259 | 0.79 | MEN1 (0.34) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21076611 | 0.77 | ESR1 (0.37) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22895111 | 0.77 | NR3C2 (0.41) | SLC6A2SLC6A4SLC6A3ESR1ESR2 | |
| SCHEMBL1090665 | 0.74 | SMN1; SMN2 (0.44) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20927101 | 0.73 | CYP3A4 (0.33) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12120613 | 0.72 | GABRA1 (0.33) | RAB9AESR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11091464-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091464-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | CYP3A4 1984/4885CYP2D6 211/4885SLC6A2 4594/4885 |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | CYP3A4 1984/4885CYP2D6 211/4885SLC6A2 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.